1138 related articles for article (PubMed ID: 25257544)
21. Evaluation of cannabimimetic effects of selected minor cannabinoids and Terpenoids in mice.
Wiley JL; Marusich JA; Blough BE; Namjoshi O; Brackeen M; Akinfiresoye LR; Walker TD; Prioleau C; Barrus DG; Gamage TF
Prog Neuropsychopharmacol Biol Psychiatry; 2024 Jun; 132():110984. PubMed ID: 38417478
[TBL] [Abstract][Full Text] [Related]
22. The Cannabinoids Effect on Bone Formation and Bone Healing.
Raphael-Mizrahi B; Gabet Y
Curr Osteoporos Rep; 2020 Oct; 18(5):433-438. PubMed ID: 32705630
[TBL] [Abstract][Full Text] [Related]
23. Differential Enantiomer-Specific Signaling of Cannabidiol at CB
Bosquez-Berger T; Wilson S; Iliopoulos-Tsoutsouvas C; Jiang S; Wager-Miller J; Nikas SP; Mackie KP; Makriyannis A; Straiker A
Mol Pharmacol; 2022 Dec; 102(6):259-268. PubMed ID: 36153039
[TBL] [Abstract][Full Text] [Related]
24. Cannabidiol Inhibits Endocannabinoid Signaling in Autaptic Hippocampal Neurons.
Straiker A; Dvorakova M; Zimmowitch A; Mackie K
Mol Pharmacol; 2018 Jul; 94(1):743-748. PubMed ID: 29669714
[TBL] [Abstract][Full Text] [Related]
25. Molecular Mechanism and Cannabinoid Pharmacology.
Schurman LD; Lu D; Kendall DA; Howlett AC; Lichtman AH
Handb Exp Pharmacol; 2020; 258():323-353. PubMed ID: 32236882
[TBL] [Abstract][Full Text] [Related]
26. Dual allosteric and orthosteric pharmacology of synthetic analog cannabidiol-dimethylheptyl, but not cannabidiol, on the cannabinoid CB
Bouma J; Broekhuis JD; van der Horst C; Kumar P; Ligresti A; van der Stelt M; Heitman LH
Biochem Pharmacol; 2023 Dec; 218():115924. PubMed ID: 37972874
[TBL] [Abstract][Full Text] [Related]
27. Involvement of a non-CB1/CB2 cannabinoid receptor in the aqueous humor outflow-enhancing effects of abnormal-cannabidiol.
Qiao Z; Kumar A; Kumar P; Song ZH
Exp Eye Res; 2012 Jul; 100():59-64. PubMed ID: 22580290
[TBL] [Abstract][Full Text] [Related]
28. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels.
De Petrocellis L; Di Marzo V
J Neuroimmune Pharmacol; 2010 Mar; 5(1):103-21. PubMed ID: 19847654
[TBL] [Abstract][Full Text] [Related]
29. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.
Pertwee RG; Thomas A; Stevenson LA; Ross RA; Varvel SA; Lichtman AH; Martin BR; Razdan RK
Br J Pharmacol; 2007 Mar; 150(5):586-94. PubMed ID: 17245367
[TBL] [Abstract][Full Text] [Related]
30. Peripheral, but not central effects of cannabidiol derivatives: mediation by CB(1) and unidentified receptors.
Fride E; Ponde D; Breuer A; Hanus L
Neuropharmacology; 2005 Jun; 48(8):1117-29. PubMed ID: 15910887
[TBL] [Abstract][Full Text] [Related]
31. The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum.
Ma YL; Weston SE; Whalley BJ; Stephens GJ
Br J Pharmacol; 2008 May; 154(1):204-15. PubMed ID: 18311186
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.
McHugh D; Tanner C; Mechoulam R; Pertwee RG; Ross RA
Mol Pharmacol; 2008 Feb; 73(2):441-50. PubMed ID: 17965195
[TBL] [Abstract][Full Text] [Related]
33. Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors.
Nader J; Rapino C; Gennequin B; Chavant F; Francheteau M; Makriyannis A; Duranti A; Maccarrone M; Solinas M; Thiriet N
Neuropharmacology; 2014 Dec; 87():214-21. PubMed ID: 24709540
[TBL] [Abstract][Full Text] [Related]
34. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond.
Pertwee RG
Addict Biol; 2008 Jun; 13(2):147-59. PubMed ID: 18482430
[TBL] [Abstract][Full Text] [Related]
35. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors.
Moreno-Martet M; Feliú A; Espejo-Porras F; Mecha M; Carrillo-Salinas FJ; Fernández-Ruiz J; Guaza C; de Lago E
Mult Scler Relat Disord; 2015 Nov; 4(6):505-11. PubMed ID: 26590655
[TBL] [Abstract][Full Text] [Related]
36. Methods evaluating cannabinoid and endocannabinoid effects on gastrointestinal functions.
Darmani NA
Methods Mol Med; 2006; 123():169-89. PubMed ID: 16506408
[TBL] [Abstract][Full Text] [Related]
37. Virtual screening using docking and molecular dynamics of cannabinoid analogs against CB
Aviz-Amador A; Contreras-Puentes N; Mercado-Camargo J
Comput Biol Chem; 2021 Dec; 95():107590. PubMed ID: 34700256
[TBL] [Abstract][Full Text] [Related]
38. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.
García C; Palomo-Garo C; García-Arencibia M; Ramos J; Pertwee R; Fernández-Ruiz J
Br J Pharmacol; 2011 Aug; 163(7):1495-506. PubMed ID: 21323909
[TBL] [Abstract][Full Text] [Related]
39. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM
J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227
[TBL] [Abstract][Full Text] [Related]
40. Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis.
Silvestri C; Paris D; Martella A; Melck D; Guadagnino I; Cawthorne M; Motta A; Di Marzo V
J Hepatol; 2015 Jun; 62(6):1382-90. PubMed ID: 25595882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
